Posts

Posted on

BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled


SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa


SUNRISE-PD is one of very few clinical trials for a Parkinson’s disease treatment to incorporate a decentralized approach option to allow for remote participation


Patient enrollment has commenced, with recruitment being supported by The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson’s Foundation


Topline data anticipated in Late 2025 or Early 2026

CARSON CITY, Nev., April 16, 2025 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that patient enrollment is now open for the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of bezisterim (NE3107) on motor and non-motor symptoms in patients with Parkinson’s disease (PD) who haven’t been treated with carbidopa/levodopa. The first patient in the trial has been enrolled, and the Company anticipates topline data to be available in late 2024 or early 2025.

Parkinson’s disease is a progressive neurodegenerative disease most often characterized by tremors, muscle rigidity, slowness of movement, postural instability, and difficulties with speech.1 Compelling evidence implicates inflammation and insulin resistance in the initiation and progression of the disease – likely both due to their respective roles in dopamine dysfunction in the brain2-6 and neurodegeneration. Current therapeutic approaches provide only symptomatic relief, but do not modify disease progression.

“Based on promising findings from our earlier Phase 2a trial in patients with moderate to severe symptoms of Parkinson’s disease, we’ve designed the SUNRISE-PD trial to explore bezisterim’s impact at an earlier stage with patients needing to go on therapy for the first time to manage their symptoms,” said Cuong Do, BioVie’s President and CEO. “We believe that together, these two trials have the potential to illustrate the applicability of an anti-inflammatory, insulin-sensitizing drug candidate in treating both early and advanced Parkinson’s disease along with providing a foundation for registrational disease-progression studies. Additionally, SUNRISE-PD is to our knowledge one of only a handful of trials to evaluate a potential treatment for Parkinson’s disease while allowing patients to participate remotely through a decentralized trial site, broadening access for this focused study population.”

SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial with a hybrid decentralized design that will last 20 weeks from the initial screening phase to the safety follow up. During the 12-week double-blind phase, approximately 60 patients will be randomized 1:1 to receive either 20 mg of bezisterim or placebo twice-daily.

As part of the trial, patients may participate either completely from their home or at a clinical site. At-home participants will be visited by study nurses who will complete study assessments with the assistance of a neurologist who will attend the visit remotely by video and supervise administration of a modified MDS-UPDRS Part III examination, which will be recorded for review and scoring by a central rating committee. If the trial’s results are positive, participants may be eligible to enter a longer-term, open-label safety study.

“A growing body of research suggests that chronic inflammation and insulin resistance play a critical role in the onset and progression of Parkinson’s disease. By targeting these two underlying mechanisms, bezisterim may offer a novel therapeutic approach distinct from current treatments, such as levodopa, which may be associated with complications like motor fluctuations and dyskinesia,” said Mark Stacy, MD, Professor of Neurology at Medical University of South Carolina and senior clinical advisor of the SUNRISE-PD trial. “The SUNRISE-PD trial will provide valuable insights into how an anti-inflammatory, insulin-sensitizing treatment may impact motor and non-motor symptoms in early Parkinson’s disease.”

“The Parkinson’s Foundation is pleased to see BioVie shares our goal of increased patient access to clinical trials with their recruitment for the SUNRISE-PD trial, which allows patients to participate remotely through a decentralized trial site in addition to standardized sites,” said James Beck, PhD, Chief Scientific Officer of the Parkinson’s Foundation. “By offering a remote participation option, this study is expanding access to clinical research for more people living with Parkinson’s and actively lowering the all-too-common barrier of geography to research participation. We look forward to seeing how this approach can improve outcomes for all who live with Parkinson’s disease.”

BioVie announced in November 2024 that the SUNRISE-PD clinical trial is fully funded. Enrollment in the trial is being supported by leading advocacy groups in the field, including The Michael J. Fox Foundation, Davis Phinney Foundation and The Parkinson’s Foundation. People with newly diagnosed Parkinson’s disease who have not been prescribed levodopa or other dopamine receptor agonists may meet qualification criteria and can visit www.sunrisePD.com to learn more.

About Parkinson’s Disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder that primarily affects movement. It is characterized by the loss of dopamine-producing neurons in the substantia nigra, a region of the brain critical for motor control. Core symptoms include tremors, muscle rigidity, bradykinesia (slowness of movement), postural instability, and difficulties with speech.1,7 Non-motor symptoms, such as cognitive impairment, mood disorders, and autonomic dysfunction, also significantly impact patients’ quality of life.8 In the early stages, symptoms are often mild and may include subtle tremors, slight movement difficulties, and changes in handwriting or facial expressions. As the disease progresses, motor symptoms become more pronounced, leading to difficulties with balance, speech, and daily activities, often requiring full-time care in later stages.9

Since the 1960s, when dopamine’s critical role in Parkinson’s disease was first identified, levodopa has remained the cornerstone of treatment, providing significant symptom relief by replenishing dopamine levels in the brain.10-11 However, long-term use is associated with complications such as motor fluctuations—where symptom control becomes less stable—and dyskinesia, involuntary movements that can become debilitating.12-14

Emerging research highlights the role of chronic inflammation and insulin resistance in the onset and progression of Parkinson’s disease. Neuroinflammation, driven by activated microglia and elevated levels of pro-inflammatory cytokines, contributes to oxidative stress and accelerates neuronal degeneration.2-4 Additionally, insulin resistance, which impairs the brain’s ability to regulate glucose metabolism, has been linked to increased neurodegeneration and worsening motor symptoms.5-6 These metabolic dysfunctions create a harmful cycle that exacerbates disease progression, underscoring the potential of anti-inflammatory and insulin-sensitizing therapies as new avenues for treatment.

About Bezisterim        
Bezisterim (NE3107) is an orally bioavailable, BBB-permeable, insulin-sensitizer that is also anti-inflammatory. In addition, it is not immunosuppressive and has a low risk of drug-drug interaction. By binding to ERK and selectively modulating NFκB activation and TNF-α production, BioVie believes that bezisterim may offer clinical improvements in several disease indications, including PD, AD and long COVID.

BioVie has conducted and reported efficacy data on its Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate bezisterim in patients who have mild-to-moderate AD (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing bezisterim-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from AD. A Phase 2 study of bezisterim in PD (NCT05083260) has been completed, and data presented at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of bezisterim and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events.

In long COVID, bezisterim has the potential to reduce neurological symptoms including fatigue and cognitive dysfunction. Persistently circulating viral spike proteins are believed to trigger TLR-4 driven activation of NFκB and the subsequent expression of inflammatory cytokines (IL-6, TNF, IFNg).

About BioVie Inc.        
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (long COVID, AD and PD) and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-κB, and the associated neuroinflammation and insulin resistance but not ERK and NFκB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com.

Forward-Looking Statements 
This press release contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project” or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

References        
1 Cleveland Clinic. Parkinson’s Disease. Last reviewed: 2022 Apr 15.
2 Jurcau A, Andronie-Cioara FL, Nistor-Cseppento DC, et al. Int J Mol Sci. 2023;24:14582.
3 Pajares M, Rojo AI, Manda G, et al. Cells. 2020;9:1687.
4 Isik S, Kiyak BY, Akbayir R, et al. Cells. 2023;12:1012.
5 Zagare A, Hemedan A, Almeida C, et al. Mov Disord. 2025;40(1):67-76.
6 Ruiz-Pozo VA, Tamayo-Trujillo R, Cadena-Ullauri S, et al. Nutrients. 2023;15(16):3585.
7 Jankovic J. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.
8 Postuma RB, Berg D, Stern M, et al. Mov Disord. 2015;30(12):1591-1601.
9 Kalia LV and Lang AE. Lancet. 2015;386(9996):896-912.
10 Hornykiewicz O. Angew Chem Int Ed. 2002;41(17):2934-2941.
11 Olanow CW, Obeso JA and Stocchi F. Lancet Neurol. 2006;5(8):677-687.
12 Ahlskog JE and Muenter MD. Mov Disord. 2001;16(3):448-458.
13 Espay AJ, Morgante F, Merola A, et al. Ann Neurol. 2018;84(6):797-811.
14 Cilia R and Akpalu A. J Neural Transm. 2020;127(5):889-916.


For Investor Relations Inquiries:
 

Contact: 
Bruce Mackle 
Managing Director 
LifeSci Advisors, LLC 
[email protected]


For Media Inquires


Melyssa Weible

Managing Partner, Elixir Health Public Relations 

Ph: +1 201-723-5705
[email protected]



Posted on

Dayforce to Announce First Quarter 2025 Financial Results on May 7th and Participate in Upcoming Investor Conferences

MINNEAPOLIS and TORONTO, April 16, 2025 (GLOBE NEWSWIRE) — Dayforce, Inc. (NYSE:DAY) (TSX:DAY), a global human capital management (HCM) leader that makes work life better, announced today the date for the release of its first quarter 2025 earnings and its participation at upcoming investor conferences.

First Quarter 2025 Earnings Date

Dayforce will release first quarter 2025 financial results before the open of regular market trading on Wednesday, May 7, 2025.

The company will host a live webcast and conference call at 8:00 a.m. Eastern Time on May 7, 2025 to discuss the aforementioned financial results. Those wishing to participate via the webcast should access the call through the Investor Relations section of the Dayforce website. Those wishing to participate via the telephone may dial in at 877-497-9071 (USA) or 201-689-8727 (International). The webcast replay will be available through the Investor Relations section of the Dayforce website.

Upcoming Investor Conferences

Members of Dayforce management will participate in the following investor conferences:

  • The J.P. Morgan Global Technology, Media and Communications Conference at the Westin Boston Seaport District Hotel in Boston, Massachusetts on Tuesday, May 13, 2025.
  • The Baird Global Consumer, Technology and Services Conference at the InterContinental New York Barclay in New York City on Tuesday, June 3, 2025.
  • The BMO Virtual Software Conference on Monday, June 9, 2025.
  • The Mizuho Technology Conference at the Conrad New York Downtown in New York City on Tuesday, June 10, 2025.

A live webcast and replay of the presentations will be available through the Dayforce Investor Relations website. Management will also be available for one-on-one and small group meetings with investors.

About Dayforce

Dayforce makes work life better. Everything we do as a global leader in HCM technology is focused on improving work for thousands of customers and millions of employees around the world. Our single, global people platform for HR, Pay, Time, Talent, and Analytics equips Dayforce customers to unlock their full workforce potential and operate with confidence. To learn how Dayforce helps create quantifiable value for organizations of all sizes and industries, visit dayforce.com.

Source: Dayforce, Inc.

For more information, contact:

David Niederman
Investor Relations
1-844-829-9499
[email protected]



Posted on

Richtech Robotics Announces an Agreement to Purchase an Approximately 20,000 Square Foot Property to Expand Its Headquarters 

New Las Vegas-based facility plans to increase manufacturing and assembly capacity by 400% and accommodate further integration of domestic supply chain

Las Vegas, NV, April 16, 2025 (GLOBE NEWSWIRE) — Richtech Robotics Inc. (Nasdaq: RR) (“Richtech Robotics” or “the Company”), a Nevada-based provider of AI-driven service robots, announced the entry of a purchase and sale agreement for the purchase of a piece of land located at 2975 Lincoln Road, Las Vegas, Nevada (“Lincoln Property”), covering approximately 20,000 square feet, to expand its headquarters. The acquisition of the Lincoln Property is scheduled to close on or before May 15, 2025, and is expected to quadruple the Company’s assembly and manufacturing footprint for its robotics solutions, supporting increased demand and future growth.

“Richtech Robotics is experiencing rapid growth in demand for our AI-powered service robots,” said Matt Casella, President of Richtech Robotics. “At the same time, we remain committed to strengthening our domestic supply chain. Staying in Las Vegas is a strategic decision for a variety of reasons, and this new facility gives us the expanded capacity and flexibility needed to scale with the increasing interest in our robotics solutions.”

The Company anticipates the new facility will ultimately result in long-term cost savings compared to their previous rental arrangement. In addition to the expanded assemble and manufacturing capacity, the new headquarters is also expected to include a dedicated studio for content creation.

As part of its continued expansion, Richtech Robotics has also signed a lease for a new office in Newark, California, located near the heart of Silicon Valley. Engineers who have undergone training at the Las Vegas headquarters will now begin working out of the Newark location, helping to further develop and deploy the Company’s AI and robotics platforms.

Richtech Robotics maintains its commitment to U.S. assembly and manufacturing, with flagship ADAM and Scorpion robot systems being engineered, developed, and assembled in the Company’s Las Vegas headquarters. These systems feature American-engineered control technologies and are powered by NVIDIA-based operating platforms. The Company also regularly seeks to expand the reach of its supply chain to increase the use of U.S. sourced materials.

About Richtech Robotics

Richtech Robotics is a provider of collaborative robotic solutions specializing in the service industry, including the hospitality and healthcare sectors. Our mission is to transform the service industry through collaborative robotic solutions that enhance the customer experience and empower businesses to achieve more. By seamlessly integrating cutting-edge automation, we aspire to create a landscape of enhanced interactions, efficiency, and innovation, propelling organizations toward unparalleled levels of excellence and satisfaction. Learn more at www.RichtechRobotics.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Such forward-looking statements include, but are not limited to, statements regarding the performance of Richtech Robotics’ products, the targeted closing date of the Lincoln Property, and the increase of manufacturing and assembly capacity as a result of the acquisition of the Lincoln Property.

These forward-looking statements are based on Richtech Robotics’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements include, among others, risks and uncertainties related to the targeted closing date of the Lincoln Property, the increase of manufacturing and assembly capacity as a result of the acquisition of the Lincoln Property, and the ability of AI-powered robotic solutions to improve efficiency. Investors should read the risk factors set forth in Richtech Robotics’ Annual Report on Form 10-K/A, filed with the SEC on March 4, 2025, the IPO registration statement and periodic reports filed with the SEC on or after the date thereof. All of Richtech Robotics’ forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. New risks and uncertainties arise over time, and it is not possible for Richtech Robotics to predict those events or how they may affect Richtech Robotics. If a change to the events and circumstances reflected in Richtech Robotics’ forward-looking statements occurs, Richtech Robotics’ business, financial condition and operating results may vary materially from those expressed in Richtech Robotics’ forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and Richtech Robotics assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Investors:
CORE IR
Matt Blazei
[email protected]

Media: 
Timothy Tanksley
Director of Marketing
Richtech Robotics, Inc
[email protected]
702-534-0050

Attachment



Posted on

The Chefs’ Warehouse to Announce First Quarter Results on April 30, 2025

RIDGEFIELD, Conn., April 16, 2025 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) today announced that the Company intends to release its financial results for the first quarter ended March 28, 2025 before the opening of the stock market on Wednesday, April 30, 2025 and host a conference call at 8:30 a.m. ET on Wednesday, April 30, 2025 to review those results.

The conference call will be webcast live from the Company’s investor relations website at http://investors.chefswarehouse.com/. An online archive of the webcast will be available on the Company’s investor relations website for 30 days.

About The Chefs’ Warehouse

The Chefs’ Warehouse, Inc. (http://www.chefswarehouse.com) is a premier distributor of specialty food products in the United States, the Middle East and Canada focused on serving the specific needs of chefs who own and/or operate some of the nation’s leading menu-driven independent restaurants, fine dining establishments, country clubs, hotels, caterers, culinary schools, bakeries, patisseries, chocolateries, cruise lines, casinos and specialty food stores. The Chefs’ Warehouse, Inc. carries and distributes more than 88,000 products to more than 50,000 customer locations throughout the United States, the Middle East and Canada.

Contact:

Investor Relations
Jim Leddy, CFO, (718) 684-8415



Posted on

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

BOTHELL, Wash., April 16, 2025 (GLOBE NEWSWIRE) —
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, President and co-CEO, will present a Company overview at the Life Science Innovation Northwest (LSINW) 2025 Conference on Wednesday, April 23, 2025 at 3:00 p.m. Pacific time. The conference is being held April 23-24 at the Seattle Convention Center.

About Life Science Innovation Northwest

Life Science Innovation Northwest (LSINW) is the Pacific Northwest’s largest annual life science conference. This event brings together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and feature some of the most compelling life science breakthroughs of our time. Bringing together over 700 attendees, LSINW features 80+ company and research institution presentations, keynote addresses from industry leaders, engaging panel discussions on emerging trends, a dynamic startup fast pitch showdown, insightful poster presentations, and more – making it the must-attend event for the PNW’s life science community. More information is available here.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Contact:

Alliance Advisors IR
Jody Cain
310-691-7100
[email protected]

# # #



Posted on

Evolus Announces Commercial Launch of Evolysse™

Evolus Announces Commercial Launch of Evolysse™

NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the commercial launch date for Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection, scheduled for Friday, April 18th.

To support the introduction, Evolus will initiate a comprehensive educational rollout beginning with a national Evolus Academy webcast for healthcare practitioners on April 18th with several thousand attendees expected to participate. Ahead of the webcast, the company has already begun an early experience program by sending product to over 1,000 key accounts, including key opinion leaders (KOLs), clinical investigators, and leading practices. This approach enables providers to explore the performance and versatility of Evolysse™ injectable HA gels for the correction of dynamic facial wrinkles and folds, such as nasolabial folds, which will accelerate comfort, confidence, and integration of the products into clinical practice.

The Evolysse™ collection marks the company’s second commercial aesthetics product, following the successful launch of Jeuveau® in 2019. Since its launch, Jeuveau® has become the fastest-growing neurotoxin in the U.S. for four consecutive years and has now captured over 14% of the U.S. market and penetrated over 50% of aesthetic clinics. With over 15,000 purchasing accounts, Evolysse™ will launch into an established customer base who will gain access to Evolysse™ Form and Evolysse™ Smooth, helping to drive immediate and impactful momentum in the U.S. injectable HA market.

“With the introduction of Evolysse™, we are bringing together the fastest growing toxin in the category with the first new innovation in HA technology in over a decade,” said David Moatazedi, President and Chief Executive Officer of Evolus. “This is more than a product launch, it is the introduction of differentiated injectable HA gels that are grounded in clinical science and designed to meet the evolving needs of consumers seeking natural-looking results. By pairing this innovative Cold-X™ technology with the commercial strength we’ve built with Jeuveau®, we are well-positioned to expand our leadership with a differentiated injectable portfolio.”

Dr. John Fezza, MD, an award-winning oculofacial plastic surgeon, commented, “With over 30 years of experience in the aesthetics industry, I’m excited to integrate Evolysse™ into my practice. These products represent the next generation of injectable HA gels, scientifically driven, delivering natural-looking results, and backed by a strong safety profile. Evolysse™ provides a new level of confidence when treating patients who are concerned about looking overdone or unnatural. It’s exactly what my patients have been asking for.”

Representing the first breakthrough in HA technology in over a decade, Evolysse™ utilizes innovative Cold-X™ technology by Symatese which is designed to better preserve the natural structure of the HA molecule for long-lasting, natural-looking results. Evolysse™ Form and Evolysse™ Smooth address moderate to severe dynamic facial wrinkles and facial folds that may develop over time for many reasons, including the natural aging process or following weight loss. In a head-to-head clinical study against Restylane®-L, both Evolysse™ Form and Evolysse™ Smooth met the 6-month primary endpoint of non-inferiority1, with the confidence intervals and corresponding p-values (<0.001) demonstrating statistical superiority1.

Additionally, Evolysse™ Form demonstrated statistically significant differences2 compared to Restylane®-L at all measured timepoints throughout the 12-month study period. Evolysse™ Smooth showed statistically significant differences2 at 6 and 9 months, despite 20% more Restylane®-L being used3. In the head-to-head clinical study versus Restylane®-L, the safety profile of Evolysse™ Form and Evolysse™ Smooth was similar to the control.

About Evolus, Inc.

Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at www.evolus.com, and follow us on LinkedIn, X, Instagram or Facebook.

1 Based on the primary endpoint analysis for Evolysse™ Form (95% CI [-0.500, -0.032]) and Evolysse™ Smooth (95% CI [-0.416, -0.019])

2 Based on Wrinkle Severity Rating Scale (WSRS) Live Investigator Assessments (p < 0.05)

3 In the clinical study, the mean injection volume for optimal correction was 1.0 mL for Evolysse™ Smooth versus 1.2 mL for Restylane®-L

Jeuveau® and Nuceiva® are registered trademarks and Evolysse™ is a trademark of Evolus, Inc.

Cold-X™ is a trademark of Symatese Group S.A.S.

Restylane® is a trademark of Galderma S.A.

Evolus Contacts:

Investors:

Nareg Sagherian

Vice President, Head of Global Investor Relations and Corporate Communications

Tel: 248-202-9267

Email: [email protected]

Media:

Email: [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Luxury Women Men Biotechnology Health Cosmetics Consumer Pharmaceutical Retail

MEDIA:

Logo
Logo
Posted on

UiPath Recognized as a Leader in the Everest Group Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2025

UiPath Recognized as a Leader in the Everest Group Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2025

UiPath is positioned as a Leader among the 29 technology providers for its vision, capabilities, and market impact of its trusted, scalable, and open platform that is driving agentic automation

NEW YORK–(BUSINESS WIRE)–
UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced that it has been named a Leader in Intelligent Document Processing for the third consecutive year in the Everest Group Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2025. Leaders are recognized for their innovation, and continued investments in intelligent document processing solutions—including developments in agentic AI, GenAI, and LLM-driven capabilities, all while prioritizing security and compliance.

UiPath is a Leader among the 29 technology providers assessed in the Everest Group IDP PEAK Matrix®, a report that analyzes AI technologies such as LLMs, computer vision, natural language processing (NLP), and machine/deep learning to classify and extract information from structured, semi-structured, and unstructured documents. UiPath is also positioned as a Leader in the analysis of 10 Banking and Financial Services (BFS) IDP products.

UiPath enables businesses to understand, optimize, and automate complex processes end-to-end, unlocking new levels of growth, efficiency, and innovation at lower cost and less risk. The UiPath Platform™ accelerates a shift toward a new era of automation—agentic automation—a progressive leap from RPA that combines AI agents, robots, people, and models to deliver AI transformation enterprise-wide for end-to-end processes and drives autonomy and faster decision-making. The combination of robots and agents extends the scope and impact of automation and enables humans to reach their full potential and revolutionize industries such as BFS.

“Most data generated in an enterprise is often unstructured and locked away in complex documents. This poses a challenge for enterprises and AI agents to perform autonomously. Enterprises need to leverage advanced intelligent document processing (IDP) capabilities that make the data easily accessible and actionable to address this challenge,” said Mark Geene, SVP & General Manager of AI Products at UiPath. “As an established leader in the IDP market, UiPath is uniquely positioned to provide customers with solutions that help them gain business insights from any structured or unstructured documents. With the recently announced UiPath Intelligent Xtraction and Processing, or IXP – a multi-modal, generative model based, data classification and extraction experience – we are helping customers identify and extract the information they need from documents and communications, so they can automate more and unlock greater value from AI and automation. The ‘X’ in IXP not only represents extraction but also the growing number of diverse content and data types supported.”

“UiPath maintains its position as a Leader in the Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2025 by achieving strong growth driven by innovation. Some of UiPath’s latest advancements include an expanding library of pre-built solutions for use cases across industries and process areas, Autopilot for UiPath Studio, a new prompt-driven capability for unstructured, and high-complexity documents, and ongoing investments in agentic automation,” said Vaibhav Bansal, Vice President, Everest Group. “Clients have also expressed their satisfaction with the cognitive features of the platform including out-of-the-box (OOTB) generative AI capabilities, ability to integrate with multiple systems, and scalability of the platform.”

There is an increased demand for specialized processing capabilities to tackle document-intensive processes in the BFS industry. UiPath has been named a Leader in the analysis of 10 BFS IDP products for the advanced capabilities it provides to enable BFS customers to extract, interpret, and process data from documents. UiPath customers, like one of the largest credit unions in the state of Florida, are leveraging UiPath IXP document understanding capabilities to automatically extract, interpret, and process data from loan packages, consolidating the information for easier review. This has reduced manual workloads, mitigated errors, and reduced fraud losses by approximately $800,000.

UiPath AI enhancements for IDP:

  • UiPath IXP (Intelligent Xtraction & Processing): is a multi-modal data classification and extraction experience that leverages GenAI and specialized models to unlock enterprise data and reduce time to production. It brings together existing and category-leading IDP capabilities (Document Understanding and Communications Mining) with a new, in private preview, prompt-driven capability for unstructured, and high-complexity documents called generative extraction for unstructured and complex documents.
  • UiPath DocPath and CommPath: specialized large language models (LLMs) that enable out-of-the-box processing of any document or message, with increased accuracy, speed, and scale. Both LLMs are now in general availability.
  • Active learning: allows for anyone to easily train their own models with active guidance from AI, no machine learning or coding skills are required.
  • Generative validation: uses GenAI to validate Document Understanding model outputs. It offers a “second opinion” on the data extracted from documents, reducing the workload of human annotators. This reduces the time spent on human validation, decreases average handling time, and boosts automation rates by up to 200%.
  • Industry-specific IDP offerings: provide tailored, pre-trained IDP models out-of-the-box for industries such as the public sector, healthcare, insurance, and financial services to accelerate end-to-end execution of document processing.
  • Unstructured Document Processing: GenAI opens the opportunity to extract data from complex documents such as contracts, lease agreements, legal briefs, and any type of long-form unstructured document.

The Everest Group Intelligent Document Processing Products PEAK Matrix® Assessment is a yearly assessment providing analysis and insights on IDP technology providers and their products to assist enterprises in their selection processes. The findings, which are based on an evaluation of providers’ impact on the market, overarching vision and product capabilities and support, are seen as benchmarks in standards and quality for the industry. As part of the evaluations, providers are classified into Leaders, Major Contenders, and Aspirants, based on key dimensions.

Register for a copy of the Everest Group Intelligent Document Processing (IDP) Products PEAK Matrix® Assessment 2025 research report here.

Disclaimer

Licensed extracts taken from Everest Group’s PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group’s analysts and included in Everest Group’s PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports.

About UiPath

UiPath (NYSE: PATH) develops AI technology that mirrors human intelligence with ever-increasing sophistication, transforming how businesses operate, innovate, and compete. The UiPath Platform™ accelerates the shift toward a new era of agentic automation—one where agents, robots, people, and models integrate seamlessly to drive autonomy and smarter decision-making. With a focus on security, accuracy, and resiliency, UiPath is committed to shaping a world where AI enhances human potential and revolutionizes industries. For more information, visit www.uipath.com.

Media

UiPath

[email protected]

Investor Relations

UiPath

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Data Management Other Technology Technology Artificial Intelligence Software

MEDIA:

Logo
Logo
Posted on

Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft’s Board of Directors at the 2025 Annual Meeting

Engine Capital Nominates Two Highly Qualified and Independent Candidates for Election to Lyft’s Board of Directors at the 2025 Annual Meeting

Intends to File Preliminary Proxy Statement and Provides Overview of the Case for Shareholder-Driven Change at Lyft Following Years of Value Destruction

NEW YORK–(BUSINESS WIRE)–
Engine Capital LP (together with its affiliates, “Engine” or “we”), which owns approximately one percent of the outstanding common shares of Lyft, Inc. (NASDAQ: LYFT) (“Lyft” or the “Company”), today announced that it is filing a preliminary proxy statement in connection with its nomination of two highly qualified and independent candidates – Alan L. Bazaar and Daniel B. Silvers – for election to the Company’s Board of Directors (the “Board”) at the 2025 Annual Meeting of Shareholders (the “Annual Meeting”).

Arnaud Ajdler, Founder and Portfolio Manager of Engine, commented:

“There is an urgent need for shareholder-driven change in Lyft’s boardroom, which is unfortunately dominated by misaligned founders and independent directors with insufficient public market experience. A majority of the Board has been in place as Lyft has delivered negative total shareholder returns and perpetually underperformed the market and its closest peer – Uber Technologies, Inc. – across every relevant time period, including the past one, three and five years. These directors have also consistently diluted shareholders and maintained an array of insular governance policies, such as a dual-class share structure that is completely unjustifiable with the founders holding small equity stakes and no longer retaining executive roles. As all of this has occurred, the Board has failed to adopt an accretive capital allocation policy and make effective use of the Company’s large net cash position and strong free cash flow generation.

This election is about sending a message to Lyft’s Board that the status quo is no longer tenable and shareholders want change. In recent months, we have privately provided value-enhancing ideas and shared the names of several independent director candidates with significant public market experience and backgrounds in areas such as capital allocation, modern corporate governance, corporate transformations and strategic transactions. Time and again, Lyft’s leadership has rebuffed us and has shown no interest in avoiding a contest. The level of closed-mindedness towards our director candidates was such that the Nominating and Corporate Governance Committee didn’t even offer to interview our nominees. This is what happens when two founders who collectively own less than 2.5% of the Company control 30% of the vote and make the Board unaccountable to its shareholders.

Although our preference was to reach a compromise and support a turnaround through private engagement, we now feel compelled to proceed with a campaign to elect two excellent directors who can help fill evident experience and skill gaps on Lyft’s Board. Messrs. Bazaar and Silvers possess additive public market experience and finance expertise, as well as a commitment to championing the interests of all the Company’s shareholders. As we work to elect these individuals and spotlight Lyft’s glaring issues, we will remain open to exploring a constructive resolution with the Company.”

Director Candidate Bios:

Alan L. Bazaar

Mr. Bazaar is an experienced public company director and investment manager with expertise in corporate finance and governance, including structuring executive compensation plans.

  • CEO of Hollow Brook Wealth Management, an investment advisory services firm.
  • Member of the board of directors of Orthofix Medical Inc. (NASDAQ: OFIX), a medical technology company.
  • Former Managing Director and Portfolio Manager at Richard L. Scott Investments, LLC, a private investment firm where he co-managed the public equity portfolio.
  • Former Supervisory Senior Consultant at Arthur Anderson LLP, where he worked in the Assurance and Financial Buyer’s Practices group and in the Business Fraud and Investigation Services unit.
  • Former member of the board of directors of Wireless Telecom Group, Inc. (NYSE AMERICAN: WTT), PDL BioPharma, Inc. (formerly NASDAQ: PDLI), Hudson Global, Inc. (NASDAQ: HSON), Sparton Corporation (formerly NYSE: SPA), LoJack Corporation (formerly NASDAQ: LOJN), NTS, Inc. (formerly NYSE AMERICAN: NTS) and Media Sciences International, Inc. (formerly NASDAQ: MSII).

Daniel B. Silvers

Mr. Silvers has considerable public company director and C-level executive experience, as well as expertise in corporate finance, capital allocation, capital markets and governance.

  • Managing Member of Matthews Lane Capital Partners, an investment firm.
  • Executive Chairman of Winventory, Inc., a tech-enabled event ticketing management partner.
  • Member of the board of directors of MRC Global, Inc. (NYSE: MRC).
  • Former Chief Executive Officer and director of Leisure Acquisition Corp. (NASDAQ: LACQ), a special purpose acquisition company, and former Executive Vice President and Chief Strategy Officer at Inspired Entertainment, Inc. (NASDAQ: INSE), a gaming technology company.
  • Former member of the board of directors of Avid Technology, Inc. (NASDAQ: AVID), PICO Holdings, Inc. (NASDAQ: PICO), Forestar Group Inc. (NYSE: FOR), Ashford Hospitality Prime (NYSE: AHP), International Game Technology PLC (NYSE: IGT) and Universal Health Services, Inc. (NYSE: UHS).

***

About Engine Capital

Engine Capital LP is a value-oriented special situations fund that invests both actively and passively in companies undergoing change.

CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

Engine Capital LP (“Engine Capital”), together with the other participants named herein (collectively, “Engine”), intends to file a preliminary proxy statement and an accompanying BLUE universal proxy card with the Securities and Exchange Commission (“SEC”) to be used to solicit votes for the election of its slate of director nominees at the 2025 annual meeting of stockholders of Lyft, Inc., a Delaware corporation (the “Company”).

ENGINE STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING A BLUE UNIVERSAL PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEBSITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR.

The participants in the proxy solicitation are expected to be Engine Capital, Engine Jet Capital, L.P. (“Engine Jet”), Engine Lift Capital, LP (“Engine Lift”), Engine Capital Management, LP (“Engine Management”), Engine Capital Management GP, LLC (“Engine GP”), Engine Investments, LLC (“Engine Investments”), Engine Investments II, LLC (“Engine Investments II”), Arnaud Ajdler, Alan L. Bazaar and Daniel B. Silvers (collectively, the “Participants”).

As of the date hereof, Engine Capital directly beneficially owned 2,772,208 shares of Class A Common Stock, par value $0.00001 per share (the “Common Stock”), of the Company. As of the date hereof, Engine Jet directly beneficially owned 278,862 shares of Common Stock. As of the date hereof, Engine Lift directly beneficially owned 284,605 shares of Common Stock. Engine Management, as the investment manager of each of Engine Capital, Engine Jet and Engine Lift, may be deemed the beneficial owner of the 3,335,675 shares of Common Stock owned directly by Engine Capital, Engine Jet and Engine Lift. Engine GP, as the general partner of Engine Management, may be deemed the beneficial owner of the 3,335,675 shares of Common Stock owned directly by Engine Capital, Engine Jet and Engine Lift. Engine Investments, as the general partner of each of Engine Capital and Engine Jet, may be deemed the beneficial owner of the 3,051,070 shares of Common Stock owned directly by Engine Capital and Engine Jet. Engine Investments II, as the general partner of Engine Lift, may be deemed the beneficial owner of the 284,605 shares of Common Stock owned directly by Engine Lift. Mr. Ajdler, as the Managing Partner of Engine Management, and the Managing Member of each of Engine GP, Engine Investments and Engine Investments II, may be deemed the beneficial owner of the 3,335,675 shares of Common Stock directly owned by Engine Capital, Engine Jet and Engine Lift. As of the date hereof, neither Messrs. Bazaar nor Silvers beneficially owned any shares of Common Stock.

For Investors:

Engine Capital LP

212-321-0048

[email protected]

For Media:

Longacre Square Partners LLC

Greg Marose / Bela Kirpalani, 646-386-0091

[email protected] / [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Posted on

Deep Track Capital Comments on Dynavax Technologies’ Rejection of Most Recent Settlement Offer

Deep Track Capital Comments on Dynavax Technologies’ Rejection of Most Recent Settlement Offer

Believes Company’s Unwillingness to Reach Mutually Acceptable Resolution – And Opposition to Giving Shareholders a Voice in the Boardroom – Underscores the Board’s Entrenchment and the Clear Need for Investor-Driven Change

GREENWICH, Conn.–(BUSINESS WIRE)–
Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”) is one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.34% of the Company’s outstanding shares. Today Deep Track commented on the Company’s disclosure that the Board of Directors (the “Board”) has rejected a settlement proposal in connection with its nomination of four highly qualified candidates for election to the Board at the 2025 Annual Meeting of Shareholders (the “Annual Meeting”).

Deep Track issued the following statement:

“We have consistently tried to work with Dynavax to find a mutually agreeable path forward that would be in the best interests of all shareholders. Our recent three-part proposal to the Company was designed to ensure that a shareholder representative would be in the boardroom and to avoid a costly and distracting proxy contest. The terms of our proposal were as follows:

  • Deep Track nominees Brett Erkman and Donald Santel would be appointed to the Board;
  • Two long-tenured incumbent directors would step down; and
  • The Board would rebalance its classes such that there are three directors in each (with Mr. Erkman and Mr. Santel added to any class except the one up for election in 2026).

Unfortunately, Dynavax swiftly rejected this proposed settlement, and merely reiterated a prior proposal that it has now put forth for a third time. In yet another sign of the Board’s entrenchment, it has refused to compromise and seems set on not having a representative of one of its largest shareholders as a director. It is highly disappointing that the Board continues to act so unreasonably – and disregard shareholders’ best interests – by refusing to negotiate toward a resolution despite various proposals from us. This behavior is made even worse by the fact that we are the second largest shareholder in Dynavax and long-term investors in the Company – not a typical “activist.”

Now is not the time to continue fighting with a major shareholder in an effort to protect the Board’s status quo. It is the time to critically evaluate the Company’s strategy and ensure it is pursuing the best path forward for all stakeholders – including by eventually eliminating Hepatitis B.

While we remain open to discussions around how to resolve this situation in an amicable fashion, we are committed to protecting the best interests of all Dynavax shareholders and ensuring their voices are heard. The need for urgent change is clear and we continue to believe that the addition of our four nominees would provide critical independence, shareholder perspective, and relevant expertise to the Board. In our view, the supportive outreach we have received from our fellow investors to date affirms the strength of our case for change and we look forward to further dialogue with other shareholders in the weeks to come.”

About Deep Track Capital

Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. We develop long term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies. In addition to capital, we seek to invest our time and expertise, while leveraging our network for the benefit of our partners. We aim to lead transactions while building large syndicates, and also to invest in rounds led by other qualified investors.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

The information herein contains “forward-looking statements.” Specific forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and include, without limitation, words such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “potential,” “targets,” “forecasts,” “seeks,” “could,” “should” or the negative of such terms or other variations on such terms or comparable terminology. Similarly, statements that describe our objectives, plans or goals are forward-looking. Forward-looking statements are subject to various risks and uncertainties and assumptions. There can be no assurance that any idea or assumption herein is, or will be proven, correct. If one or more of the risks or uncertainties materialize, or if any of the underlying assumptions of Deep Track Capital, LP (“Deep Track”) or any of the other participants in the proxy solicitation described herein prove to be incorrect, the actual results may vary materially from outcomes indicated by these statements. Accordingly, forward looking statements should not be regarded as a representation by Deep Track that the future plans, estimates or expectations contemplated will ever be achieved.

Certain statements and information included herein may have been sourced from third parties. Deep Track does not make any representations regarding the accuracy, completeness or timeliness of such third party statements or information. Except as may be expressly set forth herein, permission to cite such statements or information has neither been sought nor obtained from such third parties. Any such statements or information should not be viewed as an indication of support from such third parties for the views expressed herein.

Deep Track disclaims any obligation to update the information herein or to disclose the results of any revisions that may be made to any projected results or forward-looking statements herein to reflect events or circumstances after the date of such information, projected results or statements or to reflect the occurrence of anticipated or unanticipated events

CERTAIN INFORMATION CONCERNING THE PARTICIPANTS

Deep Track and the other Participants (as defined below) have filed a preliminary proxy statement and accompanying WHITE universal proxy card with the Securities and Exchange Commission (the “SEC”) to be used to solicit proxies for, among other matters, the election of its slate of director nominees at the 2025 annual stockholders meeting (the “2025 Annual Meeting”) of Dynavax Technologies Corporation, a Delaware corporation (“DVAX”). Promptly after filing its definitive proxy statement with the SEC, Deep Track will furnish the definitive proxy statement and accompanying WHITE universal proxy card to some or all of the stockholders entitled to vote at the 2025 Annual Meeting.

The participants in the proxy solicitation are Deep Track, Deep Track Biotechnology Master Fund, Ltd. (the “Record Stockholder”), David Kroin (all of the foregoing persons, collectively, the “Deep Track Parties”), Brett A. Erkman, Jeffrey S. Farrow, Michael Mullette and Donald J. Santel (such individuals, collectively with the Deep Track Parties, the “Participants”).

As of the date hereof, the Deep Track Parties beneficially own an aggregate of 17,791,486 shares (the “Deep Track Shares”) of the common stock, par value $0.001 per share, of DVAX (the “Common Stock”). The Deep Track Shares collectively represent approximately 14.34% of the outstanding shares of Common Stock based on 124,070,829 shares of Common Stock outstanding as of February 18, 2025 as reported in DVAX’s Annual Report on Form 10-K for the year ended December 31, 2024. Each of the Deep Track Parties may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) all of the Deep Track Shares. As of the date hereof, none of the other Participants beneficially own any shares of Common Stock.

IMPORTANT INFORMATION AND WHERE TO FIND IT

DEEP TRACK STRONGLY ADVISES ALL STOCKHOLDERS OF DVAX TO READ THE PRELIMINARY PROXY STATEMENT, ANY AMENDMENTS OR SUPPLEMENTS TO SUCH PROXY STATEMENT, AND OTHER PROXY MATERIALS FILED BY DEEP TRACK WITH THE SEC BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEBSITE AT WWW.SEC.GOV. THE DEFINITIVE PROXY STATEMENT, WHEN FILED, AND OTHER RELEVANT DOCUMENTS, WILL ALSO BE AVAILABLE BY DIRECTING A REQUEST TO THE PARTICIPANTS’ PROXY SOLICITOR, INNISFREE M&A INCORPORATED, 501 MADISON AVENUE, 20th FLOOR, NEW YORK, NY 10022 (STOCKHOLDERS CAN CALL TOLL-FREE: (877)-687-1865)

Investor Contact

Innisfree M&A Incorporated

Scott Winter / Gabrielle Wolf

+1 212-750-5833

Media Contact

Longacre Square Partners

[email protected]

KEYWORDS: United States North America Connecticut

INDUSTRY KEYWORDS: Asset Management Professional Services Finance

MEDIA:

Posted on

Partnership with Cosm Reinforces Evolv Technology’s Sports Industry Position as Innovation Leader

Partnership with Cosm Reinforces Evolv Technology’s Sports Industry Position as Innovation Leader

Evolv brings advanced fan-friendly screening experience to Cosm’s initial sites in Los Angeles and Dallas

WALTHAM, Mass.–(BUSINESS WIRE)–
Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced that it recently entered a partnership with Cosm, the immersive entertainment company pioneering news ways to experience sports and entertainment content. The partnership brings Evolv’s advanced Express® systems to Cosm’s first two locations, in the Los Angeles and Dallas metro areas. Express will be used to help deliver the secure, fast, and convenient entry screening process at the Cosm sites for major events that patrons would expect at a professional sports stadium or arena.

The partnership kicked off in December 2024.

“Cosm is introducing fans to what we call ‘Shared Reality,’ transporting fans to the best seats in the house for marquee events across sports, art, & entertainment with an immersive experience,” said Corey Breton, Head of Venues Cosm. “We knew that our technologically advanced venues needed entry screening to match, making Evolv the clear choice.”

“It’s especially gratifying to partner with Cosm,” said John Baier, Evolv’s Vice President of Sports. “We at Evolv pride ourselves on our technological innovations, but it is reaffirmed when another clear technology leader validates that belief by selecting Evolv Express for a critical part of their operations. In sports there’s a saying that ‘game recognizes game,’ and we believe this partnership is proof of that.”

The deployments in metro-Los Angeles and Dallas broaden Evolv’s growing sports and entertainment presence in both markets. In greater Los Angeles, Express is also deployed at SoFi Stadium, Crypto.com Arena, the Hollywood Bowl, and the Honda Center in Orange County. Similarly, in the DFW Metroplex, several sports and entertainment facilities join Evolv’s growing customer roster.

About Evolv

Evolv (NASDAQ: EVLV) is designed to transform human security to make a safer, faster, and better experience for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces, using industry leading artificial intelligence (AI)-powered screening and analytics. Its mission is to transform security to create a safer world to live, work, learn, and play. Evolv has digitally transformed the gateways in many places where people gather by enabling seamless integration combined with powerful analytics and insights. Evolv’s advanced systems have scanned more than a billion people since 2019. Evolv has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT) as well as the Security Industry Association (SIA) New Products and Solutions (NPS) Award in the Law Enforcement/Public Safety/Guarding Systems category, as well as Sport Business Journal’s (SBJ) awards for “Best In Fan Experience Technology” and “Best In Sports Technology”. Evolv®, Evolv Express®, Evolv Insights®, Evolv Visual Gun Detection™, Evolv eXpedite™, and Evolv Eva™ are registered trademarks or trademarks of Evolv Technologies Holdings, Inc. in the United States and other jurisdictions. For more information, visit evolv.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend for such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements made in the quotes from directors and statements regarding the Company’s execution of its strategy, financial and operational performance and growth and creating value for stakeholders. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results and actions to be materially different from any future results or actions expressed or implied by the forward-looking statements, including, but not limited to, the factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on February 29, 2024, as any such factors may be updated from time to time in our other filings with the SEC, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, as well as risks related to our leadership transition. The forward-looking statements in this press release are based upon information available to us as of the date hereof, and while we believe such information forms a reasonable basis for such statements, it may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events or otherwise.

Evolv Media Contact:

Alexandra Smith Ozerkis

[email protected]

Evolv Investor Contact:

Brian Norris

[email protected]

KEYWORDS: United States North America Massachusetts California Texas

INDUSTRY KEYWORDS: Mobile/Wireless Technology Sports General Sports Entertainment Security Software Events/Concerts General Entertainment Artificial Intelligence

MEDIA:

Logo
Logo